Episode Details

In this episode of Global Economic Press, Alex Brady discusses the evolving landscape of telehealth and GLP-1 pricing, highlighting Ozari Health's significant contributions. Ozari Health, a New York-based telehealth company, has announced updated pricing data for its nationwide platform, offering compounded Semaglutide from eighty-six dollars per month and Tirzepatide from one hundred twenty-five dollars per month. This initiative is part of their effort to provide transparent pricing without membership fees or long-term contracts. The company has also released the latest edition of its GLP-1 Telehealth Pricing Index, which tracks actual patient costs across more than ninety online GLP-1 providers. For more information, visit Ozari Health's website.

The podcast delves into the complexities of the GLP-1 market, where advertised prices often differ from real monthly costs due to hidden fees and requirements. Ozari Health's Pricing Index aims to clarify these discrepancies by providing a verified reference for GLP-1 treatment costs as of late two thousand twenty-six. The dataset, available under a Creative Commons license, is accessible on their website and Hugging Face, allowing free reuse with attribution. Ozari Health's telehealth platform connects patients with licensed providers and partners with accredited pharmacies to ensure quality and compliance. However, it's important to note that compounded Semaglutide and Tirzepatide are not approved by the Food and Drug Administration, and prescriptions require a licensed provider's review. To explore eligibility or view the full Pricing Index, visit Ozari Health's website.